Roche Seeks Partnerships, Innovation In China Rather Than Outsourcing
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel targets that are best and first in class with solid IP and potential to change standard of care qualify as partnering opportunities.
You may also be interested in...
Roche Sets Groundwork For Rapid Expansion In China Through R&D Partnerships
BEIJING - Roche is laying the groundwork for a major new phase in expansion across China through partnerships with promising pharmaceutical research outfits and biotechnology start-ups, according to senior Roche executives
Roche Pharma Japan General Manager and Asia Regional Head-Pharma Partnering Mark Noguchi In Hot Pursuit Of Sources Of Innovation in Asia: An Interview with PharmAsia News
During the last few weeks Roche has been in hot pursuit of sources of innovation, including the proposed acquisition of partner Genentech. In the same week it acquired antibody screening company Arius, RNAi company Mirus and made three more deals that the company will not announce. Roche Pharma Japan General Manager and Asia Regional Head-Pharma Partnering Mark Noguchi sat down with the PharmAsia News Australia bureau to discuss what Roche is looking for in its partners and its current partnership with Roche's Japan partner Chugai.
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.